Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials

Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in.

On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials.

The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products.

The stock has surged by over 1% in the past month.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Biotech Stocks with Huge Upside Potential and 10 Unstoppable Dividend Stocks to Buy Now

Disclosure. None.